TY - JOUR
T1 - Targeting Triglycerides
T2 - The Rise of Apolipoprotein C3 and Angiopoietin-Like Protein 3 Inhibitors
AU - Mansoor, Taha
AU - Nambi, Vijay
AU - Parikh, Sachin
AU - Misra, Arunima
AU - Ismayl, Mahmoud
AU - Sullivan, Claire
AU - Sperling, Laurence
AU - Virani, Salim S.
AU - Rifai, Mahmoud Al
AU - Koshy, Santhosh K.G.
AU - Abramov, Dmitry
AU - Minhas, Abdul Mannan Khan
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2025.
PY - 2025/11
Y1 - 2025/11
N2 - Hypertriglyceridemia has been proposed as a risk factor for atherosclerotic cardiovascular disease (ASCVD). Triglycerides (TG) are viewed as a marker for remnant cholesterol in triglyceride-rich lipoproteins, as this remnant cholesterol has been identified as a causal risk factor for ASCVD. The limited number of effective treatments for elevated TG has fueled the search for novel pharmacotherapy options, and multiple medication classes are being explored. Apolipoprotein C3 (APOC3) and angiopoietin-like protein 3 (ANGPTL3) are among the most promising targets. Several novel agents utilizing these pathways, including olezarsen, plozasiran, and zodasiran, are currently under development for the management of elevated TG, with olezarsen approved in 2024 for the management of familial chylomicronemia syndrome. This comprehensive review provides updated insights into the development of novel hypertriglyceridemia treatments.
AB - Hypertriglyceridemia has been proposed as a risk factor for atherosclerotic cardiovascular disease (ASCVD). Triglycerides (TG) are viewed as a marker for remnant cholesterol in triglyceride-rich lipoproteins, as this remnant cholesterol has been identified as a causal risk factor for ASCVD. The limited number of effective treatments for elevated TG has fueled the search for novel pharmacotherapy options, and multiple medication classes are being explored. Apolipoprotein C3 (APOC3) and angiopoietin-like protein 3 (ANGPTL3) are among the most promising targets. Several novel agents utilizing these pathways, including olezarsen, plozasiran, and zodasiran, are currently under development for the management of elevated TG, with olezarsen approved in 2024 for the management of familial chylomicronemia syndrome. This comprehensive review provides updated insights into the development of novel hypertriglyceridemia treatments.
UR - https://www.scopus.com/pages/publications/105010597292
U2 - 10.1007/s40256-025-00748-7
DO - 10.1007/s40256-025-00748-7
M3 - Review article
AN - SCOPUS:105010597292
SN - 1175-3277
VL - 25
SP - 749
EP - 766
JO - American Journal of Cardiovascular Drugs
JF - American Journal of Cardiovascular Drugs
IS - 6
ER -
